Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.

@article{Gridelli2014TreatmentOA,
  title={Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.},
  author={Cesare Gridelli and F. De Marinis and Federico Cappuzzo and Massimo Di Maio and Fred R Hirsch and Tony Shu Kam Mok and Floriana Morgillo and Rafael Rosell and David Robert Spigel and James C Yang and Fortunato Ciardiello},
  journal={Clinical lung cancer},
  year={2014},
  volume={15 3},
  pages={
          173-81
        }
}
The availability of targeted drugs has made the assessment of the EGFR mutation and ALK rearrangement critical in choosing the optimal treatment for patients with advanced non-small-cell lung cancer (NSCLC). In May 2013, the Italian Association of Thoracic Oncology (AIOT) organized an International Experts Panel Meeting to review strengths and limitations of the available evidence for the diagnosis and treatment of advanced NSCLC with EGFR or anaplastic lymphoma kinase (ALK) alterations and to… CONTINUE READING
Highly Cited
This paper has 41 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations